As DC immunotherapy is a promising approach to treat cancer patients, specifically targeting tumor cells and having only few side effects (49, 50), much research has focused on which pattern-recognition receptor ligands or cytokine-cocktails would generate a DC-phenotype with a favorable cytokine profile, often focusing on high IL-12 and low IL-10 levels (51–53). Here, IL10 is linked to cancer.